Show simple item record

dc.contributor.authorUgarte-Gil, M.F.
dc.contributor.authorGamboa-Cardenas, R.V.
dc.contributor.authorReátegui-Sokolova, C.
dc.contributor.authorPimentel-Quiroz, V.R.
dc.contributor.authorMedina, M.
dc.contributor.authorElera-Fitzcarrald, C.
dc.contributor.authorRodriguez-Bellido, Z.
dc.contributor.authorPastor-Asurza, C.A.
dc.contributor.authorPerich-Campos, R.A.
dc.contributor.authorAlarcón, G.S.
dc.date.accessioned2025-10-31T18:36:31Z
dc.date.available2025-10-31T18:36:31Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.12805/5420
dc.description.abstractObjective To determine the possible predictive value of self-efficacy on health-related quality of life (HRQoL) in patients with SLE. Methods Patients with SLE from the Almenara Lupus Cohort were included. Self-efficacy was ascertained with the six domains from the Patient-Reported Outcomes Measurement Information System (PROMIS) self-efficacy for managing chronic conditions. For PROMIS domains, a score of 50 is the average for a clinical population (people with a chronic condition), a higher score indicates that the respondent has greater self-efficacy. HRQoL was ascertained with the physical and mental component summary (PCS and MCS) measures of the Short-Form 36 (SF-36). Generalised estimating equations were performed, using as outcome the PCS or MCS in the subsequent visit, and the self-efficacy domain in the previous visit; multivariable models were adjusted for possible confounders. The confounders were measured in the same visit as the self-efficacy domain. Results Two-hundred and nine patients for a total of 564 visits were included; 194 (92.8%) patients were women and mean age at diagnosis was 36.4 (14.0) years. In the multivariable models, a better PCS was predicted by a better self-efficacy for managing symptoms, managing medications and treatments and managing social interactions and general self-efficacy; a better MCS was predicted by a better self-efficacy for managing daily activities, managing symptoms, managing medications and treatments and managing social interactions. Conclusion A better self-efficacy is predictive of subsequent better HRQoL, even after adjustment for possible confounders. These results should encourage clinicians to develop strategies to improve self-efficacy in patients with SLE.en_US
dc.description.sponsorshipFunding text 1: These analyses were done as a part of a Research Grant form Janssen. Additionally, the Almenara Lupus Cohort has been partially supported by Institutional grants from EsSalud (1483-GCGP-ESSALUD-2013, 1733-GCGP-ESSALUD-2014 and the 2015 Kaelin Prize 04-IETSI-ESALUD-2016), from the Pan American League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize and the 2018 H. Ralph Schumacher MD/JCR/PANLAR Prize) and from the Fundación Instituto Hipólito Unanue, Lima, Perú.; Funding text 2: MFU-G has grant support from Janssen and Pfizer and he has been speaker for GSK; RVG-C has grant support from Pfizer; CR-S and VRP-Q have grant support from Janssen. All other authors declare to have no conflicts of interest.
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.ispartofurn:issn:2053-8790
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectSystemic Lupus Erythematosus and Patient Outcomesen_US
dc.subjectSystemic Lupus Erythematosus Impact and Managementen_US
dc.titleA better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: Data from the Almenara Lupus Cohorten_US
dc.typehttps://purl.org/coar/resource_type/c_2df8fbb1
dc.identifier.doihttps://doi.org/10.1136/lupus-2022-000874
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.24
dc.type.otherResearch article
dc.identifier.journalLupus Science and Medicine
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2